Aptinyx (APTX) Set to Announce Quarterly Earnings on Thursday

Aptinyx (NASDAQ:APTX – Get Rating) will post its quarterly earnings results after the market closes on Thursday, May 12th. Analysts expect Aptinyx to post earnings of ($0.31) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Aptinyx (NASDAQ:APTX – Get Rating) last posted its quarterly earnings results on Wednesday, March 23rd. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. During the same quarter last year, the business earned ($0.20) EPS. On average, analysts expect Aptinyx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

APTX opened at $0.89 on Thursday. The firm has a market capitalization of $60.06 million, a PE ratio of -0.80 and a beta of 1.46. Aptinyx has a twelve month low of $0.84 and a twelve month high of $4.73. The firm’s 50-day moving average price is $2.11 and its 200 day moving average price is $2.50. The company has a current ratio of 20.18, a quick ratio of 20.18 and a debt-to-equity ratio of 0.15.

A number of equities analysts recently weighed in on APTX shares. Truist Financial lowered their price target on shares of Aptinyx from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, April 8th. William Blair lowered shares of Aptinyx from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 7th. BMO Capital Markets decreased their target price on shares of Aptinyx from $12.00 to $6.00 in a report on Friday, April 8th. Zacks Investment Research lowered shares of Aptinyx from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Finally, SVB Leerink decreased their target price on shares of Aptinyx from $10.00 to $4.00 and set an “outperform” rating on the stock in a report on Thursday, April 21st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $3.88.

Several institutional investors have recently added to or reduced their stakes in APTX. Royal Bank of Canada raised its stake in shares of Aptinyx by 244.5% in the 2nd quarter. Royal Bank of Canada now owns 9,288 shares of the company’s stock valued at $26,000 after acquiring an additional 6,592 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Aptinyx by 5.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 123,937 shares of the company’s stock valued at $331,000 after acquiring an additional 6,133 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in shares of Aptinyx in the 4th quarter valued at approximately $54,000. Millennium Management LLC raised its stake in shares of Aptinyx by 19.7% in the 4th quarter. Millennium Management LLC now owns 1,246,945 shares of the company’s stock valued at $3,329,000 after acquiring an additional 205,553 shares during the period. Finally, Susquehanna International Group LLP raised its stake in shares of Aptinyx by 56.8% in the 4th quarter. Susquehanna International Group LLP now owns 243,275 shares of the company’s stock valued at $650,000 after acquiring an additional 88,141 shares during the period. 55.97% of the stock is currently owned by institutional investors and hedge funds.

Aptinyx Company Profile (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

Featured Stories